Immunomodulatory compositions, methods of making, and methods of use thereof
The invention relates to new immunomodulatory compositions which comprise a cationic condensing agent, an immunomodulatory compound, and a stabilizing agent. The compositions of the invention typically form particles which have increased immunomodulatory activity as compared to immunomodulatory compounds not formulated in the compositions of the invention. Also provided are methods of making the compositions and methods for therapeutic use of the compositions.
1. An immunostimulatory particulate composition comprising a cationic condensing agent, an immunostimulatory compound, and a nonionic detergent;
wherein the cationic condensing agent is a cationic lipopeptide; and
wherein the immunostimulatory compound comprises an immunostimulatory sequence (ISS), wherein the ISS comprises nucleotide sequence 5′-CG-3′, wherein the cytosine of the nucleotide sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length.
2. The composition of claim 1 , wherein said cationic condensing agent is selected from the group consisting of polymyxins, circulins, octapeptin, and amphotericins.
3. The composition of claim 2 , wherein said cationic condensing agent is a polymyxin.
4. The composition of claim 3 , wherein said cationic condensing agent is polymyxin B.
5. The composition of claim 1 , wherein said nonionic detergent is a polyoxyethylenesorbitan detergent.
6. The composition of claim 5 , wherein said polyoxyethylenesorbitan detergent is polyoxyethylenesorbitan trioleate.
7. The composition of claim 1 , wherein said particulate composition further comprises a fatty acid.
8. The composition of claim 7 , wherein said fatty acid is a salt of oleic acid.
9. A pharmaceutical composition comprising:
a aqueous suspension of immunostimulatory particles, said composition comprising an immunostimulatory compound, a nonionic detergent, and a cationic condensing agent;
wherein the cationic condensing agent is a cationic lipopeptide; and
wherein the immunostimulatory compound comprises an immunostimulatory sequence (ISS), wherein the ISS comprises sequence 5′-CG-3′, wherein the cytosine of the sequence 5′-CG-3′is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length.
10. The composition of claim 9 , wherein said cationic condensing agent is selected from the group consisting of polymyxins, circulins, octapeptin, and amphotericins.
11. The composition of claim 10 , wherein said cationic condensing agent is a polymyxin.
12. The composition of claim 11 , wherein said cationic condensing agent is polymyxin B.
13. The composition of claim 9 , wherein said nonionic detergent is a polyoxyethylenesorbitan detergent.
14. The composition of claim 13 , wherein said polyoxyethylenesorbitan detergent is polyoxyethylenesorbitan trioleate.
15. The composition of claim 9 , wherein said particulate composition further comprises a fatty acid.
16. The composition of claim 15 , wherein said fatty acid is a salt of oleic acid.
17. The composition of claim 9 , further comprising an antigen.
18. The composition of claim 17 , wherein said antigen is selected from the group consisting of allergens and antigens associated with infectious agents.
19. An immunostimulatory particulate suspension comprising an immunostimulatory compound, a nonionic detergent, and a cationic condensing agent made by the process comprising:
(a) combining the immunostimulatory compound comprising an immunostimulatory sequence (ISS), wherein the ISS comprises sequence 5′-CG-3′, wherein the cytosine of the sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length and said nonionic detergent, thereby forming an immunostimulatory compound/nonionic detergent mixture,
(b) combining the cationic condensing agent, wherein said cationic condensing agent is a cationic lipopeptide, with said immunostimulatory compound/nonionic detergent mixture, and
(c) collecting the immunostimulatory particulate suspension.
20. A method of stimulating an immune response in an individual comprising:
administering to an individual the immunostimulatory particulate composition of claim 1 in an amount sufficient to stimulate an immune response in said individual.
21. An immunostimulatory particulate composition comprising immunostimulatory particles, said composition comprising polymyxin, an immunostimulatory compound, and a stabilizing agent;
wherein said immunostimulatory compound comprises an immunostimulatory sequence (ISS), wherein the ISS comprises nucleotide sequence 5′-CG-3′, wherein the cytosine of the nucleotide sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length; and
wherein said stabilizing agent is not a bovine serum protein.
22. The composition of claim 21 , wherein said stabilizing agent is selected from the group consisting of proteins, nonionic detergents, polymeric surfactants , cationic detergents, anionic detergents and fatty acids.
23. The composition of claim 22 , wherein said stabilizing agent is a nonionic detergent.
24. The composition of claim 23 , wherein said nonionic detergent is a polyoxyethylenesorbitan detergent.
25. The composition of claim 23 , wherein said polyoxyethylenesorbitan detergent is polyoxyethylenesorbitan trioleate.
26. The composition of claim 21 , wherein said polymyxin is polymyxin B.
27. The composition of claim 21 , wherein said particulate composition further comprises a fatty acid.
28. The composition of claim 27 , wherein said fatty acid is a salt of oleic acid.
29. The composition of claim 21 , wherein said immunostimulatory compound comprises the nucleotide sequence 5′-TCG-3′.
30. The composition of claim 21 , wherein said immunostimulatory compound comprises the nucleotide sequence 5′-purine, purine, C, G, pyrimidine, pyrimidine-3′.
31. The composition of claim 21 , wherein said immunostimulatory compound comprises at least 14 nucleotides.
32. A pharmaceutical composition comprising an aqueous suspension of immunostimulatory particles, said composition comprising polymyxin, a stabilizing agent, and an immunostimulatory compound;
wherein said immunostimulatory compound comprises an immunostimulatory sequence (ISS), wherein the ISS comprises nucleotide sequence 5′-CG-3′, wherein the cytosine of the nucleotide sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length; and
wherein said stabilizing agent is not a bovine serum protein.
33. An immunostimulatory particulate suspension comprising an immunostimulatory compound, a stabilizing agent, and polymyxin made by the process comprising:
(a) combining said immunostimulatory compound comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5′-CG-3′, wherein the cytosine of the sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length and said stabilizing agent, thereby forming an immunostimulatory/stabilizing agent mixture,
(b) combining polymyxin with said immunostimulatory/stabilizing agent mixture, and
(c) collecting the immunostimulatory particulate suspension.
34. A method of stimulating an immune response in an individual comprising:
administering to an individual the immunostimulatory particulate composition of claim 33 , in an amount sufficient to stimulate an immune response in said individual.
35. An immunostimulatory particulate composition comprising immunostimulatory particles, said particulate composition comprising a cationic condensing agent, an immunostimulatory polynucleotide, an antigen, and a stabilizing active agent;
wherein said immunostimulatory polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises sequence 5′-CG-3′, wherein the cytosine of the sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length.
36. A pharmaceutical composition comprising an antigen, an aqueous suspension of immunostimulatory particles, and a stabilizing agent,
wherein said particles comprises a cationic condensing agent, an immunostimulatory polynucleotide, and a stabilizing agent;
wherein the cationic condensing agent is a cationic lipopeptide; and
wherein the immunostimulatory polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises sequence 5′-CG-3′, wherein the cytosine of the sequence 5′-CG-3′ is unmethylated and the ISS is greater than about 6 base pairs in length and is less than about 100 base pairs in length.
37. A method of stimulating an immune response in an individual comprising: administering to an individual the immunostimulatory particulate composition of claim 35 in an amount sufficient to stimulate an immune response in said individual.